Tranexamic Acid (TXA) in Hip Arthroscopy
WithdrawnPhase 3NCT05710146
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary goal of this study will be to determine if perioperative IV Tranexamic Acid (TXA) administration will reduce intra-operative bleeding and subsequently improve visual clarity during surgery and reduce operative traction time in patients undergoing hip arthroscopy. Additionally, this study aims to determine whether IV TXA injections will reduce post-operative pain and affect hip-specific patient-reported outcomes in patients undergoing hip arthroscopy.
Study details
- Official title
- Assessing the Efficacy of Tranexamic Acid (TXA) in Hip Arthroscopy: A Randomized, Controlled Trial
- Conditions
- Hip Pain Chronic
- Hip Impingement Syndrome
- Hip Injuries
- Blood Loss
- Femoro Acetabular Impingement
- Interventions
- Drug: Tranexamic acid
- Drug: Placebo
- Sponsor
- Northwestern University
- Start date
- 2023-12
- Primary completion
- 2024-03
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age 18 years or older * Scheduled to undergo primary hip arthroscopy for any intra-articular procedure * Able to complete and understand study materials in English Exclusion Criteria: * Age under 18 years * Cannot complete and understand study materials in English * Patients undergoing revision surgery * Patients who have had previous surgery to the study joint * Patients on drugs that interfere with coagulation or TXA clearance * Patients with a known allergy to TXA * Patients with any of the following comorbidities * Bleeding and/or coagulative disorders * Renal impairment * Sickle cell disease * Thrombotic diseases * Comorbidities preventing surgery (including pregnancy)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05710146